SCHEMBL19301021

SCHEMBL19301021

CCCCCCCC(=O)OCC(COC(=O)CCC(=O)O[C@H](C)CC(=O)O)OC(=O)CCCCCCC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.73
ALDH1A1 P00352 1/20 0.73
PRKCE Q02156 2/20 0.63
PRKCQ Q04759 2/20 0.63
PRKCD Q05655 2/20 0.63
PRKCA P17252 1/20 0.63
LPAR3 Q9UBY5 6/20 0.60
LPAR1 Q92633 3/20 0.60
ENPP2 Q13822 3/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
LPAR2 Q9HBW0 2/20 0.59
MAPK1 P28482 2/20 0.56
CYP1A2 P05177 2/20 0.56
MEN1 O00255 1/20 0.56
GMNN O75496 1/20 0.56
HSP90AA1 P07900 1/20 0.56
MAPT P10636 1/20 0.56
BLM P54132 1/20 0.56
KMT2A Q03164 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19300938 0.89 ALDH1A1 (0.51) LMNAALDH1A1PRKCEPRKCQPRKCD
SCHEMBL22647858 0.89 ALDH1A1 (0.51) LMNAALDH1A1PRKCEPRKCQPRKCD
SCHEMBL345928 0.87 ALDH1A1 (0.84) LMNAALDH1A1PRKCEPRKCQPRKCD
SCHEMBL19285724 0.87 ALDH1A1 (0.84) LMNAALDH1A1PRKCEPRKCQPRKCD
SCHEMBL11782897 0.87 ALDH1A1 (0.84) LMNAALDH1A1PRKCEPRKCQPRKCD
SCHEMBL25272152 0.87 ALDH1A1 (0.84) LMNAALDH1A1PRKCEPRKCQPRKCD
SCHEMBL6014563 0.87 ALDH1A1 (0.84) LMNAALDH1A1PRKCEPRKCQPRKCD
SCHEMBL21409342 0.87 ALDH1A1 (0.84) LMNAALDH1A1PRKCEPRKCQPRKCD
SCHEMBL21472154 0.87 ALDH1A1 (0.84) LMNAALDH1A1PRKCEPRKCQPRKCD
SCHEMBL4862128 0.87 ALDH1A1 (0.84) LMNAALDH1A1PRKCEPRKCQPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200352894-A1 COMBINATION THERAPY RA CAPITAL HEALTHCARE FUND, L.P. 2020-11-12 US disclosed
US-10786476-B2 Combination therapy IMBRIA PHARMACEUTICALS, INC. (US) 2020-09-29 US disclosed
US-20190314319-A1 COMBINATION THERAPY IMBRIA PHARMACEUTICALS, INC. 2019-10-17 US disclosed
WO-2017147220-A1 COMBINATION THERAPY CARNOT, LLC (US) 2017-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200352894-A1 COMBINATION THERAPY PC, ABAT, CKMT1A; CKMT1B LMNA 2717/4885ALDH1A1 286/4885PRKCE 1474/4885
US-20190314319-A1 COMBINATION THERAPY PC, ABAT, CKMT1A; CKMT1B LMNA 2717/4885ALDH1A1 286/4885PRKCE 1474/4885
US-10786476-B2 Combination therapy PC, ABAT, CKMT1A; CKMT1B LMNA 2717/4885ALDH1A1 286/4885PRKCE 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.